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A strong B cell response is part of the immune landscape in human high-grade 
serous ovarian metastases. 
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Translational relevance: 
Little is known about how B cells interact with other players of the tumor immune 
landscape in HGSOC, especially in the context of a metastatic disease. The present 
study provides evidence for a positive role of B cells in the development of an anti-
tumor immune response at metastatic sites; an effect that can be enhanced by 
chemotherapy treatment. A better understanding of these processes is essential for 
developing new anti-cancer immunotherapy strategies. We show that it would be 
beneficial to take advantage of B cells and their immunoglobulins to boost the anti-
tumor immune response in patients with advanced stage HGSOC, in particular to 
increase DC recruitment to TLS and their antigen presenting ability. This could be 
exploited in DC-based vaccination protocols or as adjuvant to different anti-cancer 
treatments. 
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Abstract 
Purpose 
In high-grade serous ovarian cancer (HGSOC), higher densities of both B cells and 
the CD8+ T cell infiltrate were associated with a better prognosis. However, the 
precise role of B cells in the anti-tumor response remains unknown. As peritoneal 
metastases are often responsible for relapse, our aim was to characterize the role of B 
cells in the anti-tumor immune response in HGSOC metastases.  
Experimental design 
Unmatched pre and post-chemotherapy HGSOC metastases were studied. B-cell 
localization was assessed by immunostaining. Their cytokines and chemokines were 
measured by multiplex assay and their phenotype was assessed by flow cytometry. 
Further in vitro and in vivo assays highlighted the role of B cells and plasma cell IgGs 
in the development of cytotoxic responses and dendritic cell activation. 
Results 
B cells mainly infiltrated lymphoid structures in the stroma of HGSOC metastases. 
There was a strong B-cell memory response directed at a restricted repertoire of 
antigens and production of tumor-specific IgGs by plasma cells. These responses 
were enhanced by chemotherapy. Interestingly, transcript levels of CD20 correlated 
with markers of immune cytolytic responses and immune complexes with tumor-
derived IgGs stimulated the expression of the co-stimulatory molecule CD86 on 
antigen presenting cells. A positive role for B cells in the anti-tumor response was 
also supported by B cell depletion in a syngeneic mouse model of peritoneal 
metastasis. 
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Conclusions 
Our data showed that B cells infiltrating HGSOC omental metastases support the 
development of an anti-tumor response. 
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Introduction 
The immune system can both limit and promote cancer development. Immune cells 
infiltrate tumors and recent trials showed how unleashing a tumor-specific immune 
response with the use of tumor vaccines or immune checkpoint blockade can 
constitute a successful cancer therapy (1,2). The majority of cancer immunology 
studies have concentrated on the pro or anti-tumor abilities of T cells or myeloid cells. 
Less is known about the role of B cells in the tumor microenvironment, especially 
their contribution to the metastatic niche. In pre-clinical models of melanoma, 
squamous cell carcinoma and carcinogen-induced skin cancer, B cells promote tumor 
progression through the production of immune regulatory cytokines and immune 
complexes (3-5). On the other hand, in human primary tumors, the presence of B cells 
in association with tertiary lymphoid structures (TLS) in non-small cell lung 
carcinoma (NSCLC), colorectal, ovarian and pancreatic cancer has been associated 
with a better prognosis (6-9). In these tumors, the presence of both B cells and 
dendritic cells (DCs) correlated with an increase in Th1 signature, which might 
explain the correlation with better survival.  
Very few studies have described the immune landscape of human metastases. 
Lymphoid structures were identified in cutaneous metastases of melanoma patients 
(10) as well as in lung metastases of colorectal (CRC) and renal cell carcinoma (RCC) 
patients (11). Interestingly, a high infiltration of CD8+ T cells and DC-LAMP+ DCs 
correlated with an increased overall survival (OS) of patients with CRC whereas this 
correlated with decreased OS of patients with RCC (11). B cells have been described 
in TLS, however, their role in the tumor immune landscape remains unclear. In 
primary ovarian cancer biopsies, intra-tumor infiltration of CD27- atypical memory B 
cells, together with CD8+ T cells, is linked to better prognosis (12). A very recent 
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study also showed that a high infiltrate of T cells, B cells and plasma cells in primary 
tumors is linked to the presence of TLS in the microenvironment and improved 
survival of patients (13). Whether B cells behave the same way in ovarian cancer 
metastases and how they influence the anti-tumor response is unknown. 
The term ovarian cancer refers to a group of five diseases defined as high grade 
serous, low grade serous, mucinous, endometrial and clear cell carcinomas that are 
known to arise from different organs and have different molecular and transcriptomic 
profiles but all spread into the peritoneal cavity (14,15). High-grade serous ovarian 
cancer (HGSOC) is the most common subtype, representing about 70% of cases and 
the majority of deaths from ovarian cancer (14). Early detection of the disease is one 
of the biggest challenges, as most patients are diagnosed at an advanced stage with 
metastases disseminated in the peritoneal cavity. Platinum-based chemotherapy and 
surgical de-bulking represent the baseline treatment for HGSOC and can prolong 
survival, although the majority of patients eventually relapse and die of peritoneal 
disease. Therefore, understanding the biological properties of the peritoneal 
metastases and their immune infiltrate is essential to develop new treatment strategies 
that target the tumor deposits responsible for relapse. 
In order to elucidate the role of B cells in omental metastasis from HGSOC patients, 
we analyzed ninety-two omental samples obtained after surgery. B cells were mainly 
located in lymphoid aggregates, which displayed characteristic features of TLS. The 
majority of B cells had a memory phenotype, displayed a restricted clonal repertoire 
compared to peripheral healthy B cells and produced cytokines and chemokines 
known to recruit and activate anti-tumor immune cells, such as dendritic cells, T cells 
and NK cells. Using RNAseq analyses and in vivo experiments we also showed that B 
cells are implicated in immune cytotoxic responses. 
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Furthermore, B cells differentiated to plasma cells and produced immunoglobulins 
(Igs) against tumor targets. Igs can be found bound to antigen-presenting cells (APC) 
in the tumor stroma and co-culture of APCs with immune complexes (ICs) generated 
in vitro with tumor IgGs increased the expression of the co-stimulatory molecule 
CD86, suggesting that Igs might promote an anti-tumor response through potentiation 
of DC priming. Overall, our data suggest that B cells favor the development of an 
anti-tumor immune response in omental metastasis of HGSOC.  
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Materials and Methods 
Patient samples. Omental tissues were collected from high-grade serous ovarian 
cancer patients (FIGO stage III and IV) prior or following platinum-based 
chemotherapy treatment (Supplementary Table S1). Samples were either formalin 
fixed and paraffin embedded or snap frozen and stored at -80˚C or processed as fresh 
tissues. Blood samples from pre and post-chemotherapy patients were collected in 
sodium heparin tubes for plasma separation and EDTA tubes for cell analysis. Control 
blood was collected from 12 healthy volunteers. Institutional review board approval 
was granted for the Barts Gynae Tissue Bank to collect and store biological material 
and clinical information. Patients were treated at St Bartholomew’s Cancer Centre 
between 2010 and 2016 and gave written informed consent. Clinical parameters were 
collected using tissue repository databases and chart review. 
 
Cell lines. The AOCS1 cell line was kindly given by Professor David Bowtell (Peter 
MacCallum Cancer Center, Melbourne, Australia) and was established from the 
ascites of a patient diagnosed with HGSOC, Silverberg Grade 3, after second relapse. 
The G33 cell line was established in our laboratory from an omental HGSOC tumor 
collected during interval debulking surgery in 2011 (16). The cell lines have been 
authenticated. Cells were cultured in DMEM/F12 (Gibco), 10% FCS, 2mM L-
glutamine, 1% pen-strep in a 5% CO2 humidified incubator at 37˚C. Regular checks 
for mycoplasma contamination performed. 
 
Tissue processing and flow cytometry. The stroma vascular fraction (SVF) was 
isolated from fresh omentum by mechanical dissection of the tissue with a scalpel and 
collagenase D digestion for 30min at 37˚C (Roche). Digested samples were filtered 
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through 70µm strainers and the SVF were used for FACS analyses. Fresh PBMCs 
were isolated from blood samples by centrifugation with Ficoll-PaqueTM Plus (GE 
Healthcare).  
Cell suspensions were stained with different antibody panels for 30min on ice in PBS, 
2.5% bovine serum albumin and 2mM EDTA. Cells were then washed twice and 
analyzed directly by FACS or fixed in PBS 2% formalin for 10min at 4˚C before 
being analyzed. Antibodies and viability dyes are shown in supplementary Table S2. 
Appropriate fluorescence minus one (FMO) controls were used in these experiments. 
Analysis was performed using an LSR Fortessa cell analyzer (BD-Biosciences). 
 
Immunostaining of FFPE sections. Paraffin-embedded sections from HGSOC 
omental metastases were stained for CD20, CD4, CD8, IgG, IgM, CD68, Ki67, FDC, 
Myeloperoxidase (MPO) (Dako), MECA79 (Biolegend) and DC-LAMP (Sigma). 
Sections were deparaffinised in xylene for 10min and re-hydrated by successive 
immersion in 100%, 90%, 70%, 50% EtOH and H2O. Heat induced antigen retrieval 
was performed with Citrate Buffer (Vector Labs) for 20min in a pressure cooker.   
Immunohistochemistry: Slides were blocked in PBS 2.5% BSA and 2.5% goat serum 
for 40min at room temperature (RT) and biotin/streptavidin blocking buffer (Vector 
Labs) according to manufacturer’s recommendations. Primary and secondary 
antibodies were applied for 1h at RT. Enzymatic activity was revealed with the 
Vectastain ABC Elite kit (Standard) (Vector Labs) and Sigma FAST 3,3-
diaminobenzidine tablets (Sigma). Sections were counterstained with hematoxylin 
and mounted with DPX mounting medium (Sigma).  
For dual-stain immunohistochemistry, antibodies were incubated sequentially and 
revealed with the Vectastain system previously described. FAST 3,3-
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diaminobenzidine tablets were used to generate the brown color and the Immpact VIP 
peroxidase substrate kit (SK-4605 Vector labs) generated the purple color. Sections 
were mounted with Dako Faramount aqueous mounting medium. 
Brightfield pictures we taken with an Axiophot microscope (Zeiss). CD20, DC-
LAMP and MPO single stained slides were scanned using a Pannoramic Scanner (3D 
HISTECH) and analyzed with the “Tissue Studio” software 4.0 (Definiens). 
To assess numbers of MPO+ neutrophils and DC-LAMP+ DCs in lymphoid structures, 
2-5 TLS per tumor were analyzed to obtain a mean number of positive cells per TLS 
for each metastasis. Intra-vessel cells were excluded from the counts. 
Immunofluorescence: Slides were incubated for 20 min in NH4Cl (50mM) to reduce 
autofluorescence and blocked in PBS 2.5% BSA, 2.5% goat serum for 40min at RT. 
IgG staining was performed prior to any other additional staining. Subsequently, 
primary antibodies were applied overnight at 4˚C. The next day, fluorescently labeled 
secondary antibodies (Invitrogen) were incubated for 1h at RT and sections were 
mounted with Prolong gold antifade reagent containing Dapi (Thermo Fisher 
Scientific). 
The specificity of the stainings was determined using appropriate isotype controls. 
Fluorescent pictures were taken with an LSM510 confocal microscope (Zeiss). 
 
In vitro DC differentiation and activation. PBMCs were isolated from the blood of 
6 healthy volunteers by centrifugation with Ficoll-PaqueTM Plus (GE Healthcare). 
CD14+ monocytes were purified using anti-human CD14 beads (Miltenyi) and 
cultured in RPMI 10% FCS, 20ng/ml recombinant human GM-CSF and recombinant 
human IL4 (Biolegend). After 6 days, monocyte-derived DCs were re-stimulated with 
10µg/ml of IgGs (purified from protein extracts of two HGSOC omental tumors or 
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healthy plasma IgGs and pooled) for 24h hours, pre-incubated or not with 30µg of 
combined protein extracts from HGSOC cell lines, G33 and AOCS1. Expression of 
the co-stimulation marker CD86 on DCs was assessed by flow cytometry. 
 
Statistical analysis: Data are expressed as the mean of values per sample ± the 
standard error of the mean (SEM). Statistical significance for flow cytometry, 
immunohistochemistry and Mesoscale analyses was assessed using the Student’s T 
test or a non-parametric test (Mann-Whitney) when appropriate. Spearman or Pearson 
tests were used for correlation analyses. Data normal distribution was assessed using 
the D’Agostino & Pearson omnibus normality test. Data were considered significant 
from p<0.05.  
For the mouse experiment luminescence intensity values were log10 transformed 
before applying a one-way ANOVA test to account for heteroscedasticity of results. 
For BCR sequencing data analyses, we used the species richness, the Gini-Simpson 
index and the Shannon entropy as diversity indexes.  
Finally, for the RNAseq data analysis, significantly differentially expressed genes 
were identified using a double threshold of false discovery rate (FDR) < 0.05 and an 
absolute fold change  > 2. 
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Results 
 
Presence of B cells in TLS in HGSOC omentum is associated with the generation 
of memory B cell responses. 
To assess the presence and localization of B cells in HGSOC omental metastases, 
paraffin sections from unmatched biopsies taken pre (n=10) and post (n=31) 
neoadjuvant chemotherapy (NACT) were stained for the B cell marker CD20 
(Supplementary Table S3). CD20+ B cells were mainly localized in lymphoid 
aggregates in the stroma, next to tumor islets (Figure 1A and B). There was no 
significant difference in the number of B cells in pre and post NACT biopsies, 
suggesting that chemotherapy neither impairs nor increases B cell infiltration in 
omental metastases (Figure 1C). Because similar lymphoid structures were described 
in other solid cancers as TLS (7,10,17), we further characterized the B cell rich 
follicles using immunohistochemistry and immunofluorescence. We often observed a 
core of CD20+ B cells surrounded by a T-cell rich area of mainly CD4+ T cells, 
whereas CD8+ T cells were located at the periphery of the lymphoid aggregates 
(Figure 1D). In addition, high endothelial venules (HEV; blood vessels specialized in 
the recruitment of immune cells within lymphoid organs) were present, as indicated 
by MECA79 staining (Figure 1E). By double color immunohistochemistry we also 
identified areas rich in follicular dendritic cells and Ki67+ highly proliferative 
germinal center B cells surrounded by CD45RO+ memory cells (Figure 1F). Taken 
together, these features indicate the presence of TLS in HGSOC omental metastases.  
TLS are implicated in the differentiation of antigen specific B cells and development 
of memory responses (8). To assess the B cell composition of HGSOC omental 
metastases, flow cytometry analysis of cells extracted from 25 fresh HGSOC omenta 
was carried out. Results showed that a majority of omental B cells display a 
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“classical” (CD27+IgM+ and CD27+IgM-) or “atypical” (CD27-IgM-) memory 
phenotype (Figure 2A and B). Interestingly, we observed a significant increase in the 
proportion of class-switched memory B cells (CD27+IgM-) in metastases from 
NACT-treated patients compared to pre-chemotherapy patients (Supplementary 
Figure S1A). This was accompanied by a decrease in CD20+ naïve B cells after 
chemotherapy treatment, although data did not reach statistical significance. The 
extent of residual disease did not seem to impact significantly on the proportion of 
class-switched memory B cells after chemotherapy (Supplementary Figure S1A).  
The percentage of naïve B cells was on average 28.2% of CD20+ cells in omental 
metastasis (Figure 2B), lower than in patient blood (mean 47.8%; Supplementary 
Figure S1B). This difference suggested that there was an ongoing B cell response in 
HGSOC patients that drove B cell differentiation and might have taken place in TLS 
at sites of metastasis. 
Further analyses of B cell subpopulations demonstrated that a higher proportion of 
class-switched memory B cells (CD20+CD27+IgM- and CD20+CD27-IgM-) expressed 
the co-stimulatory molecule CD86 when compared to IgM+ memory (CD27+IgM+) 
and naive (CD27-IgM+) B cells (Figure 2C). No difference in CD86 expression was 
observed between pre and post chemotherapy patients (Supplementary Figure S1C). 
Nonetheless, all memory B cell subpopulations also upregulated the inhibitory 
receptor PD1, albeit to a lesser extent (Figure 2D and Supplementary Figure S1D). 
Co-expression of CD86 and PD1 on B cells was generally low (Supplementary Figure 
S1E and F).  
To investigate whether omental B cells were mounting an antigen specific response, 
we then analyzed their clonal repertoire by B cell receptor (BCR) sequencing. We 
extracted RNA from purified omental HGSOC B cells and peripheral B cells from 
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healthy individuals and sequenced the IgH portion of the B cell receptor. We report 
here three common mathematical indices of diversity calculated from the IgH 
repertoire data: the species richness (defined as the number of unique IgH clonotypes 
in the sample), the Shannon entropy (which equally weights a species richness term 
and a term that increases with increasing clonal dominance), and the Gini-Simpson 
index (which weights the dominance term more heavily than the species richness 
term).  For all diversity indices, HGSOC B cells showed decreased diversity relative 
to healthy donor B cells (Figure 2E). This observation was in accordance with an 
increase in the rate of somatic hypermutations in Igs from HGSOC omentum 
compared to healthy B cells (Figure 2F). 
So far, our results suggested that B cells in HGSOC omentum are activated, 
differentiate to a memory B cell phenotype and undergo clonal selection.  
 
B cells correlate with the infiltration of DC-LAMP+ DCs and an immune 
cytolytic signature in HGSOC omentum. 
B cells secrete pro-inflammatory and/or regulatory cytokines and chemokines that can 
influence the development of specific immune responses, as previously found in 
different cancer models (18,19). To determine how the secretome of HGSOC B cells 
could influence the anti-tumor immune response, B cells from omental metastases 
were purified and stimulated for 48h with a low dose of PMA and Ionomycin 
(PMA/Iono). The secretion of cytokines and chemokines was analyzed by 
electrochemoluminescence multiplex assay and healthy peripheral B cells were used 
as control.  
The heatmap shown in Figure 3A highlights the relationship existing between 24 
cytokines and chemokines produced by HGSOC omental B cells and suggests an 
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immune-stimulatory role for B cells. In addition to secretion of cytokines and 
chemokines (GM-CSF, IFNγ, IL12p40, CXCL10, IL7) that can broadly recruit and 
support macrophages, DCs, T cells and NK cells, tumor omental B cells produced 
significant amounts of inflammatory cytokines such as CXCL8, CCL2 and IL6, even 
in the absence of PMA/Ionomycin stimulation (Figure 3B-D). Median concentrations 
were 19694 pg/ml for CXCL8, 885.5 pg/ml for CCL2 and 51.4 pg/ml for IL6, as 
opposed to 2178 pg/ml, 2.19 pg/ml and 2.027 pg/ml respectively in HGSOC and 
healthy peripheral B cells. 
When we analyzed the expression of the CXCL8 receptors, CXCR1 and CXCR2, on 
immune cells from HGSOC omentum we observed that, in accordance with 
previously published evidence (20), granulocytes expressed the highest levels of both 
receptors, whereas DCs expressed significant but lower levels of CXCR1 and CXCR2 
(Figure 3E). B and T cells had very low expression of these two chemokine receptors. 
These results suggest that through the production of CXCL8, B cells are implicated in 
the recruitment of both DCs and granulocytes in omental metastases and more 
specifically in TLS. Given that the majority of granulocytes in HGSOC omentum are 
neutrophils (data not shown), we stained HGSOC omental tumors for the neutrophil 
marker MPO (myeloperoxidase) and DC marker DC-LAMP and assessed the 
localization of DCs and neutrophils in the tumor microenvironment (Figure 3F). 
Three times less neutrophils than DCs were observed in TLS. We next studied 
whether there was a correlation between the number of CD20+ B cells and DC-
LAMP+ DCs in HGSOC omentum. Immunohistochemistry staining and digital 
analysis of 16 FFPE sections from HGSOC omental metastases showed a significant 
correlation between the density of B cells and DCs in the stroma area of omental 
tumors (Figure 3G).  
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In lung cancer, the presence of B cell rich TLS and DCs has been linked to good 
prognosis and the development of a Th1 signature (21). Since activated DCs can 
stimulate CD8+ T cells and promote a cytotoxic response and B cells and DC 
densities were correlated in HGSOC metastases (Figure 3G), we assessed whether the 
B cell infiltrate correlated also with a cytotoxic response. To this end, we analyzed 
RNA from HGSOC omental metastasis by RNAseq and examined transcriptional 
changes between uninvolved Stage1/2 HGSOC omentum (n=6), Stage 3/4 untreated 
(n=4), chemotherapy-treated diseased omentum (bad responders) (n=7) and 
chemotherapy-treated omentum with low residual disease (good responders) (n=5). 
When comparing gene expression levels between these groups, forty-four genes, 
characteristic of a B cell signature, were significantly increased in omental metastases 
(Stage 3/4 pre and post chemo and Stage 3/4 good responders as opposed to Stage 
1/2) (Figure 4A-D). We next analyzed the correlation between the transcript levels of 
CD20 in stage 3/4 HGSOC omentum and the immune cytotoxic markers, granzyme A 
(GZMA) and perforin (PRF1) (22). Not only did we observe a strong correlation 
between the levels of CD20 and GZMA or PRF1 transcripts (Pearson r=0.73 and 0.61 
respectively; data not shown) but CD20 expression also strongly correlated with the 
geometric mean of the combined parameters (Figure 4E). This suggested that B cells 
contribute favorably to the development of an anti-tumor immune response.  
The above associations were supported by an experiment using a syngeneic mouse 
model of ovarian cancer, in which the mouse cell line ID8 is injected intraperitoneally 
and tumor growth is monitored over the course of 8 weeks. We depleted CD20+ B 
cells in tumor-bearing mice with an anti-CD20 antibody and found that B cell 
depletion was associated with an increased tumor progression (Figure 4F, left panel) 
and a reduced T cell cytotoxic activity, as indicated by decreased expression of the 
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degranulation marker CD107 from ascitic CD8+ T cells (Figure 4F, lower right 
panel). 
Collectively our results suggest that through the production of cytokines and 
chemokines that help recruit and support antigen-presenting cells, B cells could 
enhance the development of an immune cytotoxic response towards tumor cells.   
 
Immunoglobulin production by intratumor plasma cells 
Active germinal center reactions in TLS are normally associated with differentiation 
of plasma cells that secrete antigen-specific immunoglobulins. Indeed, HGSOC 
omenta appeared to contain a plasma cell infiltrate, as demonstrated by the presence 
of CD38++CD19+/-CD20-CD27+ cells (Figure 5A and 5B). Furthermore, we observed 
high levels of IgG deposits in HGSOC omenta, mainly located in stromal areas but 
also bound to tumor cells and macrophages (Figure 5C). IgM immunoglobulins were 
also detected but to a lesser extent (Supplementary Figure S2A). Mass spectrometry 
analysis of proteins extracted from three HGSOC omental metastases confirmed that 
IgG immunoglobulins represent the largest subclass, with IgM and IgA representing 
less than 15% of total antibodies. IgE immunoglobulins were not detected under these 
conditions (Supplementary Figure S2B). We next examined the amount of IgG1, 
IgG2, IgG3 and IgG4 subclasses in HGSOC omenta from different disease Stages 
(1/2 vs 3/4) with high or low residual disease (Supplementary Table S4). Figure 5D 
shows an increase in the presence of IgG1, IgG2 and IgG3 in stage 3/4 omenta 
compared to Stages 1/2 (Figure 5D and Supplementary Figure S2C). Furthermore, 
IgG3 was significantly increased in post-chemotherapy diseased samples compared to 
pre-treatment samples. On the other hand, IgG4 levels seemed to increase in Stage 3/4 
pre-chemotherapy tumors compared to Stage 1/2 uninvolved omenta but had a 
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tendency to decrease post-chemotherapy. Importantly, HGSOC patient plasma levels 
of IgG subclasses were not different from healthy controls (Supplementary Table S5 
and Supplementary Figure S2D and E), suggesting that a tumor-specific antibody 
response preferentially takes place at the tumor site in TLS.  
Next, to assess the ability of omental IgGs to recognize membrane bound and/or 
intracellular tumor antigens, we isolated immunoglobulins from three HGSOC 
omental tumors (G146, G168 and G175) and tested their reactivity towards intact or 
permeabilized tumor cells (AOCS1 and G33 HGSOC cell lines) by flow cytometry 
and immunofluorescence respectively (Supplementary Figure S3A-C). IgGs from all 
three omenta mainly targeted intracellular antigens; either cytoplasmic or nuclear 
(Supplementary Figure S3A and B), nonetheless, IgGs extracted from the G175 and 
G146 omental tumors were able to recognize antigens expressed at the surface of a 
subpopulation of the HGSOC tumor cell line AOCS1 (Supplementary Figure S3C). 
To determine the nature of these antigens we carried out immunoprecipitation 
experiments using purified tumor immunoglobulins as bait and assessed proteins 
pulled down by mass spectrometry. Total tumor lysate and control bead extracts were 
used as controls. Proteins found enriched in the IP fraction (but not in the control bead 
extracts) compared to the total tumor lysate were considered potential targets of intra-
tumor IgGs (Table 1). This assay identified a number of targets of omental IgGs, 
some of which were validated by IHC. The proteins GNA13 (Guanine nucleotide 
binding protein (G) 13), DPYSL3 (Dihydropyrimidase like 3 or CRMP4) and HSPB1 
(heat shock protein B1) were detected in paraffin sections of HGSOC omenta 
(Supplementary Figure S3D). We concluded from these experiments that the majority 
of immunoglobulins were binding antigens released in the tumor microenvironment 
after tumor cell death.  Nevertheless, the extensive deposition of immunoglobulins 
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bound to antigens, called immune complexes (ICs) could still be playing a role in the 
anti-tumor response, since ICs can activate APCs via ligation of Fc gamma receptors 
(FcγR) (23,24). Therefore, we assessed whether purified intra-tumor IgGs were 
playing a role in the activation of APCs in vitro. In these experiments we treated 
monocyte-derived DCs with tumor-derived IgGs, pre-incubated or not with protein 
extracts from HGSOC cell lines in order to generate ICs. IgGs from healthy blood, 
alone or incubated with tumor antigens, were used as controls (Figure 5E). Treatment 
of monocyte-derived DCs with in vitro generated tumor ICs significantly increased 
the expression of the co-stimulatory molecule CD86 compared to healthy IgGs in 
combination with tumor antigens. This suggested that IgGs, likely produced by intra-
tumor plasma cells, recognize tumor antigens and form ICs that contribute to the 
activation of APCs in the tumor microenvironment. 
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Discussion 
In this study we set out to elucidate the role played by B cells in HGSOC metastases 
by analyzing human biopsies. From previous studies, it was known that high levels of 
CD8+ T cell infiltration of primary human ovarian tumors were associated with an 
increased survival (25) and that patients displaying high tumor-infiltrating T cells, 
CD20+ B cells, and plasma cells exhibited an additional survival advantage (12,13). 
This was reinforced by analyses of the TCGA ovarian cancer dataset, showing a 
positive correlation between a B cell gene expression signature and progression free 
survival in immunoreactive ovarian tumors (26). However, data were limited to 
primary tumors and not peritoneal metastases, which are generally responsible for the 
high rate of recurrence in HGSOC. In our work on omental metastases, we found B 
cells in HGSOC omentum were mainly located in lymphoid structures and a high 
proportion exhibited a memory phenotype. These results were in accordance with the 
above-mentioned study demonstrating memory B cells in primary ovarian tumors, 
which correlated with a good prognosis (12). Furthermore, a similar role for B cells 
was also described in NSCLC (8). We do not have sufficient samples to assess 
correlations with survival, nonetheless our results indicate that B cells take part and 
positively influence the development of an anti-tumor response. This is in agreement 
with a pre-clinical study showing that depletion of B cells using anti-CD20 antibodies 
in the B16 melanoma model impairs CD8+ T cell anti-tumor immunity and promotes 
cancer development (27). Interestingly, we observed that depletion of B cells in the 
ID8 ovarian mouse model decreased the expression of the degranulation marker, 
CD107, on CD8+ T cells. This was accompanied by increased tumor growth and 
suggested that depletion of B cells impairs the T cell dependent anti-tumor cytotoxic 
response. In accordance with these results, RNAseq analyses of human omental 
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metastases showed CD20 transcript levels significantly correlated with levels of 
cytolytic markers (22), hence linking B cells to immune cytotoxic responses in 
patients’ metastases. 
It is interesting to note that chemotherapy neither affected the enrichment in B cell 
signature nor the density of CD20+ B cells, however, class-switched memory B cells 
were enhanced after NACT. Although we cannot rule out a direct effect of 
chemotherapy on survival and migration of B cells, it is possible to speculate that 
following chemotherapy the release of tumor antigens in the microenvironment 
provides a boost for the activation and differentiation of B cells. Nonetheless, these 
results are in accordance with studies describing the immune-stimulatory properties of 
chemotherapeutic agents such as anthracyclins, which causes immunogenic cell death 
of tumor cells (28) and platinum-based chemotherapy, shown to promote T cell 
activation and downregulation of immune-modulatory molecules on DCs (29). Our 
results indicate that chemotherapy has a positive influence also on B cell responses. 
Next, we observed that omental B cells produced a network of cytokines and 
chemokines including IFNγ, IL12, GM-CSF and CXCL10, compatible with the 
development of anti-tumor responses, most likely occurring within TLS. HGSOC 
omental B cells also secreted high amounts of CXCL8, a chemoattractant for 
neutrophils and DCs. Indeed, CXCR1 and CXCR2 receptors for CXCL8 were 
detected on omental DCs and neutrophils. Although neutrophils expressed higher 
levels of both receptors, more DCs than neutrophils infiltrated the lymphoid structures 
found in omental metastases. A more complex chemotactic network comprising 
CCL2, CXCL8, GM-CSF but also additional unidentified factors might explain this 
observation. Interestingly and in accordance with a study conducted in NSCLC (8), 
stromal densities of CD20+ B cells and DC-LAMP+ DCs correlated in omental 
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tumors. In vitro studies recently demonstrated that activated B cells could induce the 
maturation of monocyte-derived DCs, rendering them competent for T cell activation 
(30). Whether omental B cells directly support maturation of DCs in a similar fashion 
remains to be determined. Nonetheless, the spatial distribution of B cells and DCs 
within the TLS and B cell cytokine and chemokine production suggest that B cells 
promote not only DC recruitment but also their differentiation. Are B cells also 
involved in increasing DC antigen-presenting ability? In this respect, we observed a 
high deposition of IgGs in the tumor stroma, some of which were bound to APCs. 
Several factors might contribute to this stromal localization, (i) the extracellular 
matrix could impair the diffusion of IgGs, preventing them from reaching tumor cells, 
(ii) ongoing cell death due to necrosis, chemotherapy and/or immunity, which favors 
the release of antigens in the microenvironment, hence sequestering antigen-specific 
IgGs in the stroma, (iii) IgGs targeting intracellular antigens that cannot be easily 
accessible. We confirmed that intratumor IgGs preferentially target intracellular 
antigens, although some cytoplasmic proteins can be abnormally exposed at the 
surface of cancer cells (31). Nonetheless, previous studies provided evidence that Igs 
targeting intracellular antigens possess anti-cancer properties either by reaching their 
targets, possibly through internalization by cancer cells (32,33) or by activating APCs 
through FcR, which in turn stimulate T cell responses (34). In support of this latest 
hypothesis, we found that immunoglobulins from HGSOC metastases can form ICs 
with tumor antigens and promote expression of the co-activatory molecule CD86 on 
in vitro generated DCs. These results indicate that ICs present in the tumor stroma 
could increase DC antigen-presenting capabilities.  
Contrary to studies showing an increase in IgG4 antibodies in cutaneous metastases of 
melanoma patients (35), the predominance of IgG1, IgG2 and IgG3 over IgG4 
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antibodies in HGSOC metastases, especially following chemotherapy treatment, 
highlighted their potential to trigger APCs activation, through binding to activatory 
FcγRs (36,37). It is interesting to note that in post-chemotherapy omentum displaying 
low residual disease the decrease in tumor IgGs, mirrored by the decrease in the B 
cell infiltrate in the tumor, is likely to be linked to a partial resolution of the anti-
tumor immune response with a decreased number of TLS.  
In conclusion, our study demonstrated for the first time that in human metastases of 
HGSOC, B cells develop memory responses in the tumor microenvironment, likely 
via their association with TLS. In this context, their activated phenotype, secretion of 
pro-immunogenic cytokine/chemokines and production of IgGs targeting tumor 
antigens is associated with an enhanced recruitment and priming of DCs and 
promotion of immune cytotoxic responses. Our study provides supporting evidence 
that ICs of anti-tumor IgGs bound to tumor antigens could be beneficial in the clinic 
and potentiate anti-tumor responses. This approach has already been tested in a pre-
clinical study (23) and should be further explored in a cancer setting. Since we show 
that chemotherapy further enhances the anti-tumor B cell response, these new 
approaches would be compatible and aided by current treatments. 
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Table. 
Table 1. Identification of the proteins targeted by immunoglobulins in HGSOC 
omentum by mass spectrometry. 
  
G175 G168 G146
Guanine nucleotide-binding protein subunit 
alpha-13 OS=Homo sapiens GN=GNA13 PE=1 
SV=2
1.0 92.8 1750.9 550.3
Protein 4.1 OS=Homo sapiens GN=EPB41 PE=1 
SV=4 2.0 92.6 14.7 2.8
Nexilin OS=Homo sapiens GN=NEXN PE=1 SV=1 3.0 78.3 177.4
60S acidic ribosomal protein P0 OS=Homo sapiens 
GN=RPLP0 PE=1 SV=1 3.0 188.8 11.7
Myosin light chain 6B OS=Homo sapiens 
GN=MYL6B PE=1 SV=1 3.0 146.1 25.2
CD5 antigen-like OS=Homo sapiens GN=CD5L 
PE=1 SV=1 1.0 83.7 26.6
Dihydropyrimidinase-related protein 2 OS=Homo 
sapiens GN=DPYSL2 PE=1 SV=1 4.0 180.5 2.6
60S ribosomal protein L6 OS=Homo sapiens 
GN=RPL6 PE=1 SV=3 4.0 153.6 3.8
Actin, aortic smooth muscle OS=Homo sapiens 
GN=ACTA2 PE=1 SV=1 2.0 962.8 5.6
Cell surface glycoprotein MUC18 OS=Homo 
sapiens GN=MCAM PE=1 SV=2 2.0 79.2 3.3
78 kDa glucose-regulated protein OS=Homo 
sapiens GN=HSPA5 PE=1 SV=2 8.0 370.0 2.7
Filamin-C OS=Homo sapiens GN=FLNC PE=1 
SV=3 3.0 164.4 7.6
Dihydropyrimidinase-related protein 3 
OS=Homo sapiens GN=DPYSL3 PE=1 SV=1 5.0 321.9 15.9
Inter-alpha-trypsin inhibitor heavy chain H1 
OS=Homo sapiens GN=ITIH1 PE=1 SV=3 2.0 130.2 3.2
Interferon-induced GTP-binding protein Mx2 
OS=Homo sapiens GN=MX2 PE=1 SV=1 2.0 218.2 64.0
Inter-alpha-trypsin inhibitor heavy chain H4 
OS=Homo sapiens GN=ITIH4 PE=1 SV=4 4.0 164.4 4.2
AP-2 complex subunit alpha-1 OS=Homo sapiens 
GN=AP2A1 PE=1 SV=3 2.0 186.0 2.9
Keratin, type II cytoskeletal 8 OS=Homo sapiens 
GN=KRT8 PE=1 SV=7 1.0 137.5 2.7
40S ribosomal protein S20 OS=Homo sapiens 
GN=RPS20 PE=1 SV=1 2.0 103.9 3.2
Tripeptidyl-peptidase 1 OS=Homo sapiens 
GN=TPP1 PE=1 SV=2 1.0 83.1 4.4
Calreticulin OS=Homo sapiens GN=CALR PE=1 
SV=1 2.0 90.6 8.9
Hemoglobin subunit gamma-1 OS=Homo sapiens 
GN=HBG1 PE=1 SV=2 5.0 370.3 7.2
Heat shock protein beta-1 OS=Homo sapiens 
GN=HSPB1 PE=1 SV=2 5.0 115.5 5.0
Histidine-rich glycoprotein OS=Homo sapiens 
GN=HRG PE=1 SV=1 2.0 101.9 3.6
Alpha-actinin-2 OS=Homo sapiens GN=ACTN2 
PE=1 SV=1 1.0 470.3 2.6
Desmin OS=Homo sapiens GN=DES PE=1 SV=3 1.0 101.8 31.8
POTE ankyrin domain family member E OS=Homo 
sapiens GN=POTEE PE=1 SV=3 1.0 330.3 514.6
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Table and Figure legend: 
Table 1. Identification of the proteins targeted by immunoglobulins in HGSOC 
omentum by mass spectrometry. Tumor IgGs were used as bait to 
immunoprecipitate their potential targeting antigens. Proteins found significantly 
enriched in the IP fractions compared to total tumor lysate were considered potential 
targets of tumor IgGs.  
 
Figure 1. B cells in HGSOC are found in tertiary lymphoid structures. (A) 
Immunohistochemistry pictures showing two representative sections from paraffin 
embedded HGSOC omentum stained for CD20. Scale bar: 200µm. (B and C) Log2 
density of CD20+ B cells in HGSOC omental metastases. (B) Comparison of CD20+ 
B cell densities in tumor vs stromal areas (n=33). (***p≤ 0.001; Mann-Whitney test) 
(C) Comparison of CD20+ B cell densities in the stroma of unmatched HGSOC 
metastases obtained before (n=10) and after chemotherapy treatment (n=31). (D-F) 
Characterization of the B cell-rich lymphoid structures by single color 
immunohistochemistry, immunofluorescence and double color 
immunohistochemistry. (D) Identification of CD20+ B cells, CD4+ and CD8+ T cells 
within TLS. Scale bars: 50µm.  (E) Presence of MECA79+ high endothelial venules in 
TLS. Scale bars: 20µm. (F) Germinal centers of TLS contain follicular dendritic cells 
(FDC) and Ki67+ high proliferating cells surrounded by CD45RO+ memory cells. 
Scale bars: 50µm. 
 
Figure 2. Memory B cell response in HGSOC metastases. (A and B) Flow 
cytometry analysis of the B subpopulations in HGSOC omentum (n=25) showing 
differential expression of CD27 and IgM within the CD20+ cells. Representative plots 
(A) and percentages (B) of the different B cell subpopulations: IgM+ memory 
31	  	  
(CD27+IgM+), class switched memory or IgM- memory (CD27+IgM-), CD27- atypical 
memory (CD27-IgM-) and naïve (CD27-IgM+) B cells. An example of IgD expression 
in the different subpopulations is shown. (C and D) Proportion of CD86+PD1- (C) and 
PD1+CD86- (D) cells among the B cell subsets described above (n=11). (*p≤0.05; 
**p≤0.01; ***p≤0.001; Mann-Whitney test and Student’s T test).  (E and F) BCR 
sequencing of B cells from HGSOC omentum (O) (n=7) and blood (B) (n=1) 
compared to healthy peripheral B cells (ctrl) (n=7). (E) Diversity analysis of the B cell 
repertoire. Error bars: 95% confidence interval (38). (F) Analysis of hypersomatic 
mutations. IgH mutation rates for each sample (top panel). Tumor and non-tumor 
samples were binned and IgHV mutation rates compared (lower panel).  
 
Figure 3. Role of B cells in the recruitment of dendritic cells in HGSOC 
metastases. (A-D) Cytokine/chemokine secretion of HGSOC omental B cells (see 
supplementary Methods). (A) Correlation heatmap showing how the levels of the 24 
cytokines and chemokines measured in the supernatant of HGSOC B cells (n=4-10) 
vary with each other. Columns and rows represent individual cytokines and 
chemokines colored to indicate pearson’s correlation coefficient (r). (B-D) Log2 
concentrations of CXCL8, CCL2 and IL6 in the supernatant of unstimulated healthy 
peripheral B cells (n=2); PMA/Ionomycin (PMA/Iono) treated healthy peripheral B 
cells (n=5-7); unstimulated and PMA/Ionomycin treated HGSOC omental B cells 
(n=9-10). (*p≤0.05; ***p≤0.001, Student’s T test) (E) Flow cytometry analysis of 
CXCR1 (n=4) and CXCR2 (n=3) expression on CD19+ B cells; CD3+ T cells, 
CD11b++CD14+CD11c- macrophages; CD11b++CD14-CD11c- granulocytes and 
CD11b++CD14-CD11c+ dendritic cells from HGSOC omentum. (F) Representative 
immunostainings and quantification of DC-LAMP+ dendritic cells and MPO+ 
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neutrophils in CD20+ rich lymphoid structures in HGSOC omental metastases (n=7). 
Arrows indicate MPO+ cells. Scale bar: 100µm. (***p≤0.001, Student’s T test) (G) 
Correlation analysis between the log2 densities of DC-LAMP+ dendritic cells and 
CD20+ B cells in a cohort of 16 HGSOC patients (2 pre-chemotherapy and 14 post-
chemotherapy) (p≤0.05; Spearman correlation test). 
 
Figure 4. B cell signature is enriched in diseased omentum and linked to 
cytotoxic response. (A-D) Heatmap and boxplots showing an increase in expression 
of B cell signature genes in stage 3/4 pre (n=4) and post-chemotherapy (pos-
chemotherapy diseased (post dis) n=7; post-chemotherapy good responders (post 
good) n=5) vs stage 1/2 (n=6) non-involved HGSOC omentum. (*p≤0.05; **p≤0.01; 
Student’s T test). (E) Positive correlation between the geometrical mean of levels of 
expression of granzyme A (GZMA) and perforin (PRF1) versus CD20 (MS4A1) in 
HGSOC stage 3/4 omentum. (F) CD20 depletion increased tumor progression in the 
ID8 mouse model. (Left panel) Tumor progression in anti-CD20 (n=5) and IgG 
control (n=4) treated mice assessed by luciferase activity monitoring (p=0.03; Two-
way ANOVA on Log10 luminescence values). (Upper right panel) B cell (CD45+ 
CD19+) and plasma cell (CD45+ CD138+) are depleted in the ascitic fluid of αCD20 
treated ID8 mice vs IgG controls. (Lower right panel) CD107 expression by ascitic 
CD8+ T cells in αCD20 and IgG control treated ID8 mice (**p≤0.001; Student’s T 
test).  
 
Figure 5. Plasma cells are present in HGSOC omenta and IgGs deposited mainly 
in stromal areas but also on tumor cells and macrophages. (A and B) Presence of 
CD38++CD19+/-CD20-CD27+ plasma cells in HGSOC omentum (n=11). (C) Paraffin 
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sections of omental metastases were fluorescently stained for CD20, CD68 or 
Cytokeratin 7 (CK7) (red) in combination with IgG (green). Arrows indicate co-
localization of the CD68 and CK7 markers with IgG. Scale bar: 20µm. (D) Protein 
extracts isolated from frozen stage 3/4 pre-chemotherapy, post-chemotherapy 
diseased, post-chemotherapy with no/low residual disease and Stage 1/2 non involved 
omentum were tested for the presence of human IgG1, IgG2, IgG3 and IgG4 by 
ELISA. (*p<0.05, Mann Whitney). (E) Tumor derived IgGs ICs increase the 
expression of CD86 on DCs in vitro. IgGs were isolated from two tumor lysates using 
Agarose beads coupled to protein A/G and pooled. Monocyte-derived DCs (n=7) 
from healthy volunteers were then treated with tumor IgGs alone or tumor IgGs pre-
incubated with protein extracts from HGSOC tumor cells. IgGs from healthy plasma 
was used as a control. CD86 expression on DCs was assessed after 24h treatment. 
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